The MBI Group has fostered various strong connections throughout the globe over decades of experience.
This has allowed MBI to create partnerships with reliable, world-renowned institutions.
Read more

Founded in 2001 in Salzburg, Austria, Novogenia Group, which consists of various German and Austrian biotech companies, acts as a pioneer in the field of preventative genetic testing, lifestyle genetic testing, molecular diagnostics of diseases, and medical food supplements.

They offer the world’s largest network of laboratories, with over 100 medical and genetic laboratories worldwide, providing more than 3,200 different medical and genetic tests – the largest portfolio in the world.

The group employs more than 3,000 physicians and hospitals internationally in over 30 countries.

Novogenia possesses automated and high-tech genetic engineering laboratories, licensed to perform medical and genetic testing. Due to the main laboratory residing in Austria, a country with one of the strictest laws on genetic engineering in Europe, all medical and genetic testing is required to be evaluated and approved by officials before their use, meaning the laboratories observe only the highest quality of standards.

3200+

different medical and genetic tests

More than 100

medical and genetic laboratories

3000+

physicians and hospitals

Over 30

countries

a

a

Founded in 1935, Cipla is now active in over 80 countries, providing more than 1,500 authorized products across various therapeutic sectors in 50+ dosage forms.

They employ over 25,000+ employees and have achieved over 2.3 billion USD turnover. Their licensed medical treatments include Remdesivir and Molnupiravir, as well as others still being processed, such as Paxlovid.

Cipla, through the power of collaboration, has enhanced global access to innovative therapies: 

Gilead for REMDESIVIR across 127 countries

CSIR-IICT for FAVIPRAVIR

MSD for MOLNUPIRAVIR

Roche for their Antibody Cocktail (Casirivibab & Imdevimab)

Licensed BARICITINIB from Eli Elilly for hospitalized patients with COVID-19

One of their principal aims is to make healthcare and medical treatments more affordable and accessible globally – particularly through expanding their presence in key markets, such as South Africa, India, and other markets in the developing world.

Founded in 1966 in India, with the primary aim of manufacturing life-saving immuno-biologicals, such as vaccines, Serum Institute has since become the largest vaccine manufacturer in the world by the number of doses produced and sold globally – over 1.5 billion doses.

Since its founding, Serum Institute has acknowledged the issues surrounding the shortage of medical treatments and high import prices within developing countries, and has striven to combat this. Now, the company is ranked as India’s number one biotechnology company, using cutting-edge genetic and cell-based technologies and other medical specialties to manufacture highly specialized and life-saving medical supplies and treatments.

Their laboratories are some of the most modern in the world, with state-of-the-art, high-tech machinery and computerized equipment. The vaccines manufactured by Serum Institute, a list of which includes vaccines for Covid-19, Polio, Tetanus, Diphtheria, Measles, etc. to name a few, are accredited by the WHO and Geneva and are utilized in around 170 countries world-wide, globally saving millions of lives. 

World's largest

vaccine manufacturer by number of doses produced and sold globally

More than 170 countries

use Serum Institute, saving millions of lives throughout the world

65% of the children

in the world receive at least one vaccine manufactured by Serum

India's no.1

Serum Institute of India remains in 1st place as India's top biotechnology company

a

a

Founded in 1987 in Gaithersburg, Maryland, NOVAVAX, an American biotechnology company, is committed to addressing serious infectious diseases globally through the discovery, development, and delivery of innovative vaccines.

Novavax develops state-of-the-art vaccines in an effort to combat some of the world’s most pressing infectious diseases.

34+ years of
experience

1500+ employees worldwide

$2B funding secured to date since 2020

2 billion doses anually

10+ items in the pipeline

6 areas of research

Prior to 2020, company scientists developed experimental vaccines for influenza and respiratory syncytial virus (RSV), as well as Ebola and other emerging infectious diseases. During 2020, the company redirected its efforts to focus on the development and the approval of its NVX-CoV2373 vaccine for COVID-19.

Novavax’ vaccine development: from established genetic engineering to unique nanoparticles

Novavax Covid-19 vaccines do not contain the dead virus, instead only using proteins.

COVID-19 is caused by the SARS-CoV-2 virus. The virus uses a protein on its surface, known as a spike protein, to attach itself to human cells and cause an infection. Novavax makes a protein that precisely mimics the virus’ version of the spike protein. Novavax’ vaccine organizes the spike proteins into nanoparticles to help the immune system recognize the target spike. Learning to recognize the spike proteins in this way helps immune system protect you from getting sick from COVID-19. However, nanoparticles with spike proteins are just 1 of 2 important parts that make up the contents of the Novavax vaccine. The spike protein requires a “signal boost” to generate the immunity that will help protect you from COVID-19.

That signal boost comes from Novavax Matrix-M “adjuvant.” Tiny Matrix-M adjuvant particles increase the activity of the immune system when the body receives the vaccine. Together, the vaccine’s spike protein and the Matrix-M adjuvant help stimulate a protective immune response against the coronavirus. 

Novavax: COMMITTED TO MAKING A DIFFERENCE!